After seven years of debate, and 19 formal rounds of negotiations, the Trans-Pacific Partnership was agreed in October this year. Its IP provisions, which are among the most controversial, will have an impact on pharmaceutical protection, copyright, trade marks, geographical indications and enforcement, among other areas. Peter Leung provides a summary of the main points and over the following pages we look at the impact country-by-country
Unlock this content.
The content you are trying to view is exclusive to our subscribers.
Novo Nordisk losing patent rights covering Ozempic in Canada and a US Supreme Court decision favouring Ed Sheeran were also among the top talking points
Jorg Thomaier, who has been head of IP at the German pharma company since 2010, will leave later this year and hand the reins to the company’s head of patents